| dbo:abstract
|
- Seagen (ehemals Seattle Genetics) ist ein US-amerikanisches Biotechnologieunternehmen, das Therapien zur Krebsbehandlung auf Basis monoklonaler Antikörper entwickelt und vermarktet. Das Unternehmen mit Sitz in Bothell in Washington (ein Vorort von Seattle) stellt Chemoimmunkonjugate her, die monoklonale Antikörper nutzen, um zellabtötende Wirkstoffe direkt an Krebszellen abzugeben. Sie sollen die gesunden Zellen verschonen und dadurch die toxische Wirkung einer Chemotherapie verringern und die Wirksamkeit gegen den Tumor erhöhen. (de)
- Seagen (ancien Seattle Genetics) est une entreprise américaine de biotechnologie. (fr)
- Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. The company's flagship product Adcetris (brentuximab vedotin) is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union. To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development programto evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries. In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies. In January 2018, the company announced it would acquire Cascadian Therapeutics for $614 million. In September 2020, Merck & Co announced it would purchase $1 billion of Seagen's common stock, with both companies co-developing lead treatment: . In November 2022, the company announced the appointment of David R. Epstein as Chief Executive Officer and Director. (en)
|
| dbo:formerName
|
- Seattle Genetics, Inc. (en)
- (1997–2020) (en)
|
| dbo:foundingYear
| |
| dbo:industry
| |
| dbo:location
| |
| dbo:numberOfEmployees
|
- 2700 (xsd:nonNegativeInteger)
|
| dbo:owner
| |
| dbo:owningCompany
| |
| dbo:product
| |
| dbo:thumbnail
| |
| dbo:type
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 31736 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:bloomberg
| |
| dbp:formerName
|
- (en)
- Seattle Genetics, Inc. (en)
|
| dbp:google
| |
| dbp:industry
| |
| dbp:keyPeople
|
- (en)
- David R. Epstein (en)
- Roger Dansey M.D. (en)
- Todd E. Simpson (en)
|
| dbp:location
|
- Bothell, Washington, U.S. (en)
|
| dbp:logo
| |
| dbp:name
|
- Seagen (en)
- Seagen Inc. (en)
|
| dbp:numEmployees
| |
| dbp:owner
| |
| dbp:products
|
- Brentuximab vedotin and other antibody-drug conjugates (en)
|
| dbp:reuters
| |
| dbp:revenue
| |
| dbp:secCik
| |
| dbp:symbol
| |
| dbp:type
| |
| dbp:wikiPageUsesTemplate
| |
| dbp:yahoo
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Seagen (ehemals Seattle Genetics) ist ein US-amerikanisches Biotechnologieunternehmen, das Therapien zur Krebsbehandlung auf Basis monoklonaler Antikörper entwickelt und vermarktet. Das Unternehmen mit Sitz in Bothell in Washington (ein Vorort von Seattle) stellt Chemoimmunkonjugate her, die monoklonale Antikörper nutzen, um zellabtötende Wirkstoffe direkt an Krebszellen abzugeben. Sie sollen die gesunden Zellen verschonen und dadurch die toxische Wirkung einer Chemotherapie verringern und die Wirksamkeit gegen den Tumor erhöhen. (de)
- Seagen (ancien Seattle Genetics) est une entreprise américaine de biotechnologie. (fr)
- Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. (en)
|
| rdfs:label
|
- Seagen (de)
- Seagen (fr)
- Seagen (en)
|
| rdfs:seeAlso
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:homepage
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
